GSK's Shingles Vaccine Steps Closer To Catching Zostavax

GlaxoSmithKline is preparing for major filings next year for its challenger to Sanofi Pasteur MSD's Zostavax shingles vaccine, now named Shingrix (HZ/su vaccine), after promising top-line data in a second Phase III trial confirmed its benefits in an older patient population.